On September 25, 2025, U.S. President Donald Trump announced a 100% tariff on imported branded and patented pharmaceutical products, effective October 1, 2025. This policy primarily targets high-cost, branded drugs, which constitute a minority of Indian pharmaceutical exports to the U.S. While the immediate impact on Indian generic drug manufacturers appears limited, concerns persist regarding potential future tariffs on complex generics and biosimilars.